| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2017-09-09 02:55:14 UTC |
|---|
| Update Date | 2022-11-30 19:25:56 UTC |
|---|
| HMDB ID | HMDB0114861 |
|---|
| Secondary Accession Numbers | None |
|---|
| Metabolite Identification |
|---|
| Common Name | PA(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)) |
|---|
| Description | PA(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)), in particular, consists of one chain of palmitoleic acid at the C-1 position and one chain of arachidonic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids. |
|---|
| Structure | [H][C@@](COC(=O)CCCCCCC\C=C/CCCCCC)(COP(O)(O)=O)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC InChI=1S/C39H67O8P/c1-3-5-7-9-11-13-15-17-18-19-20-22-24-26-28-30-32-34-39(41)47-37(36-46-48(42,43)44)35-45-38(40)33-31-29-27-25-23-21-16-14-12-10-8-6-4-2/h11,13-14,16-18,20,22,26,28,37H,3-10,12,15,19,21,23-25,27,29-36H2,1-2H3,(H2,42,43,44)/b13-11-,16-14-,18-17-,22-20-,28-26-/t37-/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 1-Palmitoleoyl-2-arachidonoyl-sn-glycero-3-phosphate | HMDB | | 1-Palmitoleoyl-2-arachidonoyl-sn-phosphatidic acid | HMDB | | PA(16:1/20:4) | HMDB | | PA(16:1N7/20:4N6) | HMDB | | PA(16:1W7/20:4W6) | HMDB | | PA(36:5) | HMDB | | Phosphatidic acid(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)) | HMDB | | Phosphatidic acid(16:1/20:4) | HMDB | | Phosphatidic acid(16:1n7/20:4n6) | HMDB | | Phosphatidic acid(16:1W7/20:4W6) | HMDB | | Phosphatidic acid(36:5) | HMDB | | Phosphatidate(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)) | HMDB | | Phosphatidate(16:1/20:4) | HMDB | | Phosphatidate(16:1N7/20:4N6) | HMDB | | Phosphatidate(16:1W7/20:4W6) | HMDB | | Phosphatidate(36:5) | HMDB | | 1-palmitoleoyl-2-arachidonoyl-sn-glycero-3-phosphate | SMPDB, HMDB | | 1-palmitoleoyl-2-arachidonoyl-sn-phosphatidic acid | SMPDB, HMDB | | PA(16:1/20:4) | SMPDB, HMDB | | PA(16:1n7/20:4n6) | SMPDB, HMDB | | PA(16:1w7/20:4w6) | SMPDB, HMDB | | PA(36:5) | SMPDB, HMDB | | Phosphatidic acid(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)) | SMPDB, HMDB | | Phosphatidic acid(16:1/20:4) | SMPDB, HMDB | | Phosphatidic acid(16:1n7/20:4n6) | SMPDB, HMDB | | Phosphatidic acid(16:1w7/20:4w6) | SMPDB, HMDB | | Phosphatidic acid(36:5) | SMPDB, HMDB | | Phosphatidate(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)) | SMPDB, HMDB | | Phosphatidate(16:1/20:4) | SMPDB, HMDB | | Phosphatidate(16:1n7/20:4n6) | SMPDB, HMDB | | Phosphatidate(16:1w7/20:4w6) | SMPDB, HMDB | | PA(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)) | SMPDB |
|
|---|
| Chemical Formula | C39H67O8P |
|---|
| Average Molecular Weight | 694.931 |
|---|
| Monoisotopic Molecular Weight | 694.457356115 |
|---|
| IUPAC Name | [(2R)-3-[(9Z)-hexadec-9-enoyloxy]-2-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyloxy]propoxy]phosphonic acid |
|---|
| Traditional Name | (2R)-3-[(9Z)-hexadec-9-enoyloxy]-2-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyloxy]propoxyphosphonic acid |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | [H][C@@](COC(=O)CCCCCCC\C=C/CCCCCC)(COP(O)(O)=O)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC |
|---|
| InChI Identifier | InChI=1S/C39H67O8P/c1-3-5-7-9-11-13-15-17-18-19-20-22-24-26-28-30-32-34-39(41)47-37(36-46-48(42,43)44)35-45-38(40)33-31-29-27-25-23-21-16-14-12-10-8-6-4-2/h11,13-14,16-18,20,22,26,28,37H,3-10,12,15,19,21,23-25,27,29-36H2,1-2H3,(H2,42,43,44)/b13-11-,16-14-,18-17-,22-20-,28-26-/t37-/m1/s1 |
|---|
| InChI Key | KIOZPTOVNVDIEQ-NKPUTKKASA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as 1,2-diacylglycerol-3-phosphates. These are glycerol-3-phosphates in which the glycerol moiety is bonded to two aliphatic chains through ester linkages. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Glycerophospholipids |
|---|
| Sub Class | Glycerophosphates |
|---|
| Direct Parent | 1,2-diacylglycerol-3-phosphates |
|---|
| Alternative Parents | |
|---|
| Substituents | - 1,2-diacylglycerol-3-phosphate
- Fatty acid ester
- Monoalkyl phosphate
- Dicarboxylic acid or derivatives
- Fatty acyl
- Alkyl phosphate
- Phosphoric acid ester
- Organic phosphoric acid derivative
- Carboxylic acid ester
- Carboxylic acid derivative
- Hydrocarbon derivative
- Organic oxide
- Organic oxygen compound
- Carbonyl group
- Organooxygen compound
- Aliphatic acyclic compound
|
|---|
| Molecular Framework | Aliphatic acyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Naturally occurring processBiological processBiochemical pathwayMetabolic pathway- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0065719)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)) (PathBank: SMP0065720)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z)) (PathBank: SMP0065724)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z)) (PathBank: SMP0065725)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0065727)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z)) (PathBank: SMP0069245)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0069246)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)) (PathBank: SMP0069247)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)) (PathBank: SMP0074471)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:0) (PathBank: SMP0074472)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/24:0) (PathBank: SMP0074479)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/18:1(9Z)) (PathBank: SMP0077975)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:1(9Z)/16:1(9Z)) (PathBank: SMP0077977)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/16:1(9Z)) (PathBank: SMP0077985)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/18:0) (PathBank: SMP0077986)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/18:1(11Z)) (PathBank: SMP0077987)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)) (PathBank: SMP0077989)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)) (PathBank: SMP0077991)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/16:1(9Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0093241)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)) (PathBank: SMP0093242)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0093244)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/16:1(9Z)) (PathBank: SMP0093245)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0093248)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:1(9Z)/18:1(9Z)) (PathBank: SMP0093251)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0093262)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0093276)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:1(9Z)/18:1(11Z)) (PathBank: SMP0069229)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:1(9Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0069231)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/16:0) (PathBank: SMP0069235)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0069243)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0069250)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z)) (PathBank: SMP0069251)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:1(9Z)) (PathBank: SMP0069253)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0069254)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)/18:2(9Z,12Z)) (PathBank: SMP0077982)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0077983)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0077997)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)/16:1(9Z)) (PathBank: SMP0077998)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0078001)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0089741)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0093243)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/18:1(9Z)) (PathBank: SMP0093260)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:1(13Z)) (PathBank: SMP0065723)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)) (PathBank: SMP0065726)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/24:1(15Z)) (PathBank: SMP0065730)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0077993)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)/16:1(9Z)) (PathBank: SMP0093253)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)) (PathBank: SMP0099024)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)) (PathBank: SMP0099027)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/18:1(11Z)) (PathBank: SMP0069225)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/16:1(9Z)) (PathBank: SMP0021476)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:1(11Z)) (PathBank: SMP0021477)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:1(9Z)) (PathBank: SMP0021478)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:1(11Z)) (PathBank: SMP0021479)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z)) (PathBank: SMP0021480)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)) (PathBank: SMP0021483)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z)) (PathBank: SMP0021484)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z)) (PathBank: SMP0021488)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z)) (PathBank: SMP0021489)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:2(11Z,14Z)) (PathBank: SMP0032909)
- De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:3(8Z,11Z,14Z)) (PathBank: SMP0032910)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)) (PathBank: SMP0084368)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)) (PathBank: SMP0084370)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)) (PathBank: SMP0084371)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/22:0) (PathBank: SMP0099025)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/22:1(13Z)) (PathBank: SMP0099026)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)/22:0) (PathBank: SMP0099028)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)/22:1(13Z)) (PathBank: SMP0099029)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:0/22:0) (PathBank: SMP0099030)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:0/22:1(13Z)) (PathBank: SMP0099031)
- Cardiolipin Biosynthesis CL(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)/22:1(13Z)/22:1(13Z)) (PathBank: SMP0099032)
|
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. | 6.72 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 33.8453 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.89 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 5025.2 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 450.6 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 321.2 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 280.3 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 1125.3 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 1834.9 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 1082.2 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 231.5 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 3474.3 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 1178.1 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 2731.9 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 1300.8 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 715.0 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 403.2 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 817.7 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 10.9 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| PA(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)),1TMS,isomer #1 | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCC)COP(=O)(O)O[Si](C)(C)C | 4931.4 | Semi standard non polar | 33892256 | | PA(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)),1TMS,isomer #1 | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCC)COP(=O)(O)O[Si](C)(C)C | 4361.6 | Standard non polar | 33892256 | | PA(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)),1TMS,isomer #1 | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCC)COP(=O)(O)O[Si](C)(C)C | 5343.3 | Standard polar | 33892256 | | PA(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)),2TMS,isomer #1 | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCC)COP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 4911.6 | Semi standard non polar | 33892256 | | PA(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)),2TMS,isomer #1 | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCC)COP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 4329.2 | Standard non polar | 33892256 | | PA(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)),2TMS,isomer #1 | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCC)COP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 4631.9 | Standard polar | 33892256 | | PA(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)),1TBDMS,isomer #1 | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCC)COP(=O)(O)O[Si](C)(C)C(C)(C)C | 5150.0 | Semi standard non polar | 33892256 | | PA(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)),1TBDMS,isomer #1 | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCC)COP(=O)(O)O[Si](C)(C)C(C)(C)C | 4474.4 | Standard non polar | 33892256 | | PA(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)),1TBDMS,isomer #1 | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCC)COP(=O)(O)O[Si](C)(C)C(C)(C)C | 5339.3 | Standard polar | 33892256 |
|
|---|